Last reviewed · How we verify
Placebo (for Eptifibatide)
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in Phase 3 clinical trial for Eptifibatide (acute coronary syndrome, percutaneous coronary intervention).
At a glance
| Generic name | Placebo (for Eptifibatide) |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug through comparison. In this context, it serves as the control arm in a Phase 3 trial for Eptifibatide, a glycoprotein IIb/IIIa inhibitor. Any observed therapeutic benefit in the placebo group is attributed to the placebo effect rather than direct pharmacological action.
Approved indications
- Control arm in Phase 3 clinical trial for Eptifibatide (acute coronary syndrome, percutaneous coronary intervention)
Common side effects
Key clinical trials
- Multi-arm Optimization of Stroke Thrombolysis (PHASE3)
- EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED) (PHASE3)
- Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy (PHASE3)
- A Safety Study of Eptifibatide in Patients With Sickle Cell Disease (PHASE1, PHASE2)
- The INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial (INSTANT) (PHASE4)
- INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |